2014
Recent Findings on the Mechanisms Involved in Tenofovir Resistance
Iyidogan P, Anderson K. Recent Findings on the Mechanisms Involved in Tenofovir Resistance. Antiviral Chemistry And Chemotherapy 2014, 23: 217-222. PMID: 23744599, PMCID: PMC4077986, DOI: 10.3851/imp2628.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesDrug Resistance, ViralDrug SynergismHIV-1OrganophosphonatesTenofovirConceptsReverse transcriptase inhibitorsDrug resistanceResistance mechanismsNon-nucleoside reverse transcriptase inhibitorsHIV-1 infectionLong-term efficacyMechanism of RTSynergistic antiviral effectTenofovir resistanceAntiretroviral agentsCombination therapyTreatment failureAntiviral synergySafety profileTranscriptase inhibitorsHIV-1TenofovirClinical useAntiviral effectTherapyViral sequencesNucleotide analoguesRegimensEfavirenzCurrent Perspectives on HIV-1 Antiretroviral Drug Resistance
Iyidogan P, Anderson K. Current Perspectives on HIV-1 Antiretroviral Drug Resistance. Viruses 2014, 6: 4095-4139. PMID: 25341668, PMCID: PMC4213579, DOI: 10.3390/v6104095.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsAnti-Retroviral AgentsDrug Resistance, ViralHIV InfectionsHIV-1HumansMutagenesis
2012
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2′-deoxyadenosine 5′-triphosphate as inhibitors of HIV-1 reverse transcriptase
Kim J, Wang L, Li Y, Becnel K, Frey K, Garforth S, Prasad V, Schinazi R, Liotta D, Anderson K. Pre-steady state kinetic analysis of cyclobutyl derivatives of 2′-deoxyadenosine 5′-triphosphate as inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters 2012, 22: 4064-4067. PMID: 22595174, PMCID: PMC3362660, DOI: 10.1016/j.bmcl.2012.04.078.Peer-Reviewed Original Research
2006
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
Basavapathruni A, Anderson K. Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Current Pharmaceutical Design 2006, 12: 1857-65. PMID: 16724952, DOI: 10.2174/138161206776873617.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug DesignDrug Resistance, ViralHIV InfectionsHIV Reverse TranscriptaseHumansModels, MolecularMolecular StructureReverse Transcriptase InhibitorsConceptsNonnucleoside reverse transcriptase inhibitorsReverse transcriptase inhibitorsTranscriptase inhibitorsHuman immunodeficiency virus type 1 infectionResistance to nonnucleoside reverse transcriptase inhibitorsTreatment of human immunodeficiency virus type 1 infectionType 1 infectionFood and Drug AdministrationU.S. Food and Drug AdministrationCombination therapyDevelopment of resistanceMechanism of actionHIV-1 reverse transcriptase inhibitorsDrug AdministrationNonnucleosideNonnucleoside HIV-1 reverse transcriptase inhibitorNonnucleoside inhibitorsFeatures of inhibitionPotential new inhibitorsInhibitorsAmino acid substitutionsBiochemical featuresMolecular mechanismsNew inhibitorsAcid substitutions